Sein métastatique RH+
DESTINY-Breast06 (D9670C00001)
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Paris, Saint-Cloud
JEAN-YVES PIERGA, ETIENNE BRAIN